Way Stations in Progress — Burgeoning Treatment Options for IgA Nephropathy
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Atrasentan in Patients with IgA Nephropathy
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
Two years of empagliflozin slowed kidney disease progression or cardiovascular death. In this post-trial study, empagliflozin had additional cardiorenal benefits after discontinuation.
The New England...
Science behind the Study: Linking a Neurodevelopmental Disorder with a lncRNA Deletion
This editorial describes the science behind a study linking a severe neurodevelopmental disorder with deletions in a gene (CHASERR) that encodes a long noncoding...
